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Aims:  Women with systemic lupus erythematosus (SLE) have an increased risk of 
cardiovascular disease (CVD).  Traditional CVD and disease related risk factors have been 
implicated, but do not fully account for this increased risk.  Visceral adipose is most strongly 
associated with vascular dysfunction and metabolic disorder than other adipose regions.  
Perivascular adipose tissue (PVAT) is a visceral adipose depot in close proximity to blood 
vessels, which may have more direct influence over vascular function and progression of CVD.  
We hypothesized that SLE patients have increased PVAT surrounding the descending thoracic 
aorta than healthy control subjects.  For both SLE and control subjects, we examined the relation 
between PVAT and vascular calcification of the aorta (AC) and coronary arteries (CAC). 
Methods:  Using EBT, we quantified the PVAT of the descending thoracic aortic PVAT in SLE 
(n=135) and age/race matched controls (n=152).  Participants were non-diabetic and free of 
CVD.  CAC and AC were quantified using Agatston scores and the PVAT was quantified using 
standard attenuation values for adipose tissue (–190 to –30 HU) on commercially available 
software.  The total PVAT volume (tPVAT) was calculated by summing the areas and 
multiplying by the length of the participant’s aorta.   
Results:  The SLE women were more likely to be hypertensive (p<0.0001) and had a larger 
waist to hip ratio (p=0.001) than controls reflecting a different adipose distribution.  The SLE 
group had a greater tPVAT than the control group (p=0.0071) despite no differences in BMI 
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(p=0.26), or metabolic syndrome (MS, p=0.17).  Total PVAT remained associated with SLE 
after adjusting for CVD risk factors including BMI (1.025[1.0-1.1], p=0.022), but was attenuated 
to non-significance with inflammatory factors (p=0.34).  In a logistic regression analysis, tPVAT 
was associated with AC (1.073[1.043- 1.103],p<0.0001), which remained significant after 
adjustment for CVD and inflammatory factors including BMI (p<0.0007) and MS (p<0.0004).  
The tPVAT association with CAC (1.051[1.03-1.07],p<0.0001) was non-significant with BMI 
(p>0.075) and attenuated with MS (p<0.047) when adjusted for CVD or inflammatory factors.   
Conclusions:   Total PVAT is greater in clinically CVD-free SLE versus control participants and 
is associated with AC independent of overall adiposity.  This work contributes to the field of 
public health elucidating the mechanisms of CVD progression through PVAT in SLE patients 
and ultimately in the general population.  
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1.0  INTRODUCTION 
1.1 CARDIOVASCULAR DISEASE AND WOMEN’S HEALTH 
Cardiovascular disease (CVD) and in particular coronary heart disease (CHD) and stroke 
are the leading causes of death of women in America and of all major developed countries 
including emerging economies.  Each year, more women than men have strokes and the presence 
of hypertension in women is also higher than in men after 65 years of age.[1]  Updated 
guidelines from the American Heart Association on women’s health report that  despite the 
increased awareness of CVD in women, reducing major risk factors, and improved treatment 
options, more deaths occur due to CVD than cancer, chronic lower respiratory disease, 
Alzheimer disease, and accidents combined.[1]   
 Along with unique risk factors associated with age and gender, there may also be 
differences in effective treatment and prevention between the genders as well.  Lifestyle 
approaches such as weight loss, exercise and a healthy diet are perhaps the most cost effective 
measure to controlling adverse CVD outcomes.  The presence of comorbidities and lack of 
consistent lifestyle modification can make lowering the risk of developing CVD or future CV 
events more difficult.[1]  Other options for controlling the progression of CVD include 
preventive care measures through medication to manage hypertension and blood pressure.  
Current estimates from the World Health Organization suggest that if the currently available 
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guidelines were properly adhered to then adverse CVD outcomes could be reduced by nearly 
80%.[2] 
1.2 ATHEROSCLEROSIS 
Lipid accumulation is a well established mechanism in the development of atheromas 
within the vascular wall, which burdens the vasculature resulting in CVD.  However, studies 
have shown that atherosclerosis is not merely an imbalance of circulating and accumulating 
lipids within the vascular wall, which create cores susceptible to rupture and thrombosis.  The 
pathophysiology of atherosclerotic lesion formation is intricate and is now regarded as an 
inflammatory disease.[3]  With this new classification, the role of inflammation and immune 
response become important constituents in the initiation and progression of CVD.  Initially the 
inflammation was thought to be more local within the vicinity of the athero-lesion and the idea of 
systemic inflammation was not considered.[4]  In addition to the myriad of cellular components 
and the circulating lipid, a cascade of events and pro-atherogenic response of inflammatory 
factors including vascular cell adhesion molecule -1 (VCAM-1), monocyte chemoattractant 
protein (MCP-1), interferon-γ (IFN- γ), oxidized low density lipoprotein (ox-LDL), heat shock 
proteins ( HSPs), tumor necrosis factor-α (TNF-α)  and other soluble factors such as 
homocysteine, complement, c-reactive protein (CRP), CD40 and CD40-ligand (CD40L) also 
contribute to the progression and inflammatory cycle of atherosclerosis. 
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1.2.1 Athero-lesion Development and Immunity 
Clinical manifestations of atherosclerosis do not occur until the atheroma becomes 
complex. An overabundance of smooth muscle cells (SMCs) contribute to extracellular matrix 
(ECM) thickening of the vascular wall creating a stenosis within the lumen, which either 
impedes blood flow or creates unstable plaque prone to rupture.  In pro-atherogenic conditions, 
such as hypertension, hyperglycemia, hypercholesterolemia, and smoking, endothelial cells 
(ECs) express molecular adhesion molecules such as VCAM-1 and Pselectin attracting monoytes 
and other leukocytes. [5, 6] 
Fatty streaks are precursors to plaques filled with lipid-laden macrophage foam-cells.  
The monocyte and macrophage are inflammatory cells of the innate immune system with a 
significant role and presence throughout the atheroma development and plaque formation. 
Chemoattractant factors such as MCP-1 are upregulated on endothelial cells (ECs) due to low 
shear stress, injury, or dysfunction and direct progression of leukocytes into the fatty streak.  The 
monocytes release matrix metalloprotease-9 (MMP-9) degrading the collagen type IV constituent 
of the ECM to enter the intimal layer.  Once in the intimal layer, the monocytes mature into 
macrophages through upregulation of monocyte colony stimulating factor (M-CSF). [7]  The 
pattern-recognition scavenger receptors on macrophages involved in innate immunity are also 
upregulated by M-CSF.  Monocytes also express toll like receptors (TLR1, -2, and -4) which are 
also pattern recognition receptors and are upregulated during inflammation. [8] 
The macrophage engulfs lipoproteins and other foreign factors within the developing 
lesion becoming a foam cell.  Macrophages secrete many inflammatory propagating factors 
including TNF-α and interleukin-1β (IL-1 β) which upregulate adhesion molecules (e.g. VCAM-
1), chemokines (e.g.MCP-1), growth factors (e.g.  M-CSF), and proteases (e.g. MMP9) 
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instigating the inflammatory cycle again, but from within the athero-lesion.   Other innate 
immune cells such as mast cells, natural killer cells, and neutrophils are not nearly as abundant as 
the monocyte/macrophage in the progression of the athero-lesion.  Interestingly, high circulating 
neutrophil counts predict MI better than total white blood cell, lymphocyte or monocyte 
circulating count. [9]  The complement cascade is also a part of the innate immune system.  
Complement protein C3 plays a critical role in complement activation and is required for both 
the classical and alternative pathways.  C3 cleavage products become ligands for leukocyte 
complement receptors thus targeting the foreign body for clearance.[10]  Complement protein C3 
has been found in atheromas and is produced by adipose tissue. 
Dendritic cells (DCs) are the messengers between innate and adaptive immunity and are 
found in atherosclerotic plaques with increasing numbers associated with lesion complexity.[11] 
Oxidized LDL and TNFα attract and adhere dendritic cells to the endothelium and initiate their 
migration into the intima.[12] T helper 1 cells (CD4+)are the most common T-cells present in 
human and experimental models of atherosclerosis and are produced when DCs and pre-T helper 
cells form an immunological synapse. [13] [14]  These same CD4+ cells express CD40 ligand 
(CD40L) which activates inflammatory cells including ECs, VSMCs, macrophages and platelets, 
which all contribute to atherosclerotic lesion development. [15] [16] 
Adipocytes and the cellular constituents of adipose tissue release many of the 
aforementioned factors involved in both innate and adaptive immunity including complement 
components, cytokines and chemokines including TNFα, IL-6 and MCP factors and other 
circulating inflammatory markers. [17]  
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1.3 OBESITY AND ADIPOSE 
Obesity is a CVD risk factor and is linked to mechanisms involved in coronary CVD 
including atherosclerosis, hypercholesterolemia, hypercoagulability,  platelet dysfunction, insulin 
resistance, type 2 diabetes and metabolic syndrome.[18]  Adipose tissue was once thought to be 
inert and more of a structural support, but is now considered the largest endocrine organ of the 
body involving a chronic inflammatory process inducing both innate and adaptive immune 
responses.[4, 19]   
Adipose tissue is located either subcutaneously or viscerally and in many different 
depots.  Adipose tissue can also be found ectopically within organs and muscle tissue.  Studies 
have shown that differences in adipose distribution and in particular the intra-abdominal or 
visceral adipose volume is associated more strongly with CVD than subcutaneous adipose tissue 
volume.[20, 21]  Adipose tissue also has its own anti- and pro-atherogenic cytokines which can 
initiate many of the mechanisms linking obesity to CVD including systemic inflammation.[22]   
Recently, smaller visceral adipose depots such as epicardial and pericardial have garnered 
increased attention due to their anatomical proximity to the myocardium and coronary arteries 
and their dual cardioprotective and pathological pro-inflammatory roles.[23-26]  The epicardial 
adipose surrounding the coronary arteries could also be considered a perivascular adipose depot 
and this concept has initiated studies involving the perivascular adipose tissue surrounding other 
vasculature including the aorta.[27]  The perivascular adipose tissue surrounding the descending 
thoracic aorta is readily discernable through CT scans.[28, 29]  An association between coronary 
artery and aortic calcification has been confirmed within CVD-free participants of the 
Framingham Heart Study Offspring cohort.[29]  Further quantification of the perivascular 
adipose volume and determining the association with CVD risks and other subclinical CVD 
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measures will provide valuable information into the development and role of this small visceral 
adipose depot in the progression of CVD. 
1.3.1 Cellular Components of Adipose  
Adipose is composed of a heterogeneous mixture of cell types, which play a role in both 
adipocyte cell function and overall adipose tissue metabolism and include adipocytes, 
preadipocytes, fibroblasts, and leukocytes which include lymphocytes (e.g.Tcells and 
Bcells),monocytes and macrophages.[30]  In both mouse and human adipose tissue, different 
inflammatory cell types including macrophages and Tcells, have distinct subpopulations 
dependent on a lean or obese states. [30-37]  Resident macrophages (5-10% of adipose 
tissue)help to maintain a healthy adipose state.  However, the proliferation of hypertrophic 
adipocytes and adipose dysfunction is marked by an increase in macrophage infiltration (60% of 
adipose tissue with weight gain) contributing to and sustaining an inflammatory state.[32, 38, 39]   
Most of these same cell types can be found in atherosclerotic lesions in an inflammatory 
capacity.  
The adipocyte is sensitive to infections and cytokine-mediated inflammatory signals and 
can activate inflammatory response and induce expression and secretion of TNF-α, plasminogen 
activator inhibitor-1 (PAI-1), IL-1, IL-6, IL-8, IL-10, and IL-15, leukemia inhibitory factor, 
hepatocyte growth factor, serum amyloid A-3 (SAA3),  macrophage migration inhibitory factor, 
haptoglobin, complement factors B, D, and C3, prostaglandin E2, and potential adipokine 
inflammatory modulators such as leptin, adiponectin, and resistin. [40] The relation of adipose to 
these inflammatory biomarkers shows a link that adipose is more similar to an immune organ, 
e.g. the liver.[4]  Adipose tissue is not the only contributor to systemic inflammation, but may 
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also control the upregulation of secreted inflammatory proteins through the liver and other 
inflammatory producing tissue.  These pro-inflammatory factors are modifiable, increasing with 
weight gain and decreasing with weight loss.[41, 42]  
1.4 INFLAMMATORY FACTORS OF ATHEROSCLEROSIS AND ADIPOSE 
Inflammatory markers may be considered cardiovascular risk factors due to the number 
of studies linking obesity, atherosclerosis, and inflammation.  One of the most studied circulating 
inflammatory markers is C-reactive protein (CRP), which is related to obesity  and CVD risk and 
is associated with insulin resistance, diabetes, metabolic syndrome, hypertension, smoking, and 
dyslipidemia [43]  This acute phase reactant is produced in the liver, released during an 
inflammatory state, and predicts CVD in both healthy and unhealthy populations.[44]  CRP is 
linearly correlated with BMI and in particular adipose distribution as measured by waist to hip 
ratio.  Numerous epidemiological studies have defined significant associations between high 
sensitivity CRP (hsCRP) and underlying atherosclerosis, risk of recurring CV events among 
those with established disease, and incidence of first CV events among those at risk for 
atherosclerosis.[45]  
Plasminogen Activator Inhibitor-1(PAI-1) is another circulating inflammatory marker 
which regulates the coagulation cascade and is enhanced in inflammatory and obese states.  PAI-
1 is derived from platelets and endothelium, but can also be produced by adipocytes.[46, 47]  
Increased PAI-1 decreases the rate of fibrinolysis , which creates a hypercoagulable state when 
combined with increased clotting factors and platelet activation and is associated with increased 
CVD risk [48] 
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TNF α is produced by macrophages in an inflammatory state including atherogenesis and 
is also produced by adipose tissue. [17]  An increase in circulating TNF α is associated with an 
increase in adipose mass.  Interleukin-6 (IL-6) stimulates acute-phase proteins including CRP 
and SAA3.  This action instigates the innate immune system to protect tissue and causes 
inflammation.  [49] IL-6  is secreted by Tcells, macrophages and adipose tissue and circulating 
levels are higher with increased adipose tissue.   
Another inflammatory marker primarily secreted from visceral adipose depots with 
higher levels in obese populations is angiotensinogen.[50, 51]  This circulating inflammatory 
marker contributes to angiogenesis, hypertension, and atheromatous alterations and contributes 
to vascular inflammation through upregulation of EC expression of VCAM-1, intracellular 
adhesion molecule-1 (ICAM-1), Eselectin and MCP-1.[51, 52]  VCAM-1, ICAM-1 and Eselectin 
recruit leukocytes to athero-lesion sites and ICAM-1 and Eselectin are markers of subclinical 
atherosclerosis.[53]  In addition, EC expression of ICAM and VCAM are increased with 
increased fat mass.[17]  Vascular endothelial growth factor (VEGF) functions in the 
development of hypertension and angiogenesis and is particularly elevated in visceral adipose 
tissue.  The volume of adipose tissue is able to expand through vascularization of the adipose 
depot through expression of VEGF, with increased obesity resulting in increased adipose 
expression of VEGF.[54]  
Along with CRP, fibrinogen and SAA3 are also acute phase reactants that are increased 
in inflammatory states.  Elevated levels of fibrinogen are associated with traditional CVD risk 
factors and are independent risk factors for CVD.[55]  Fibrinogen binds and contributes to 
platelet aggregation, promotes fibrin formation, and increases plasma viscosity.[55]  In addition, 
fibrinogen levels increase with increased fat mass.[17] Serum amyloid A3 is produced by many 
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tissues including adipocytes.  Circulating levels are elevated in obese and diabetic patients and 
SAA3 also acts as a chemoattractant inducing remodeling through matrix metalloproteinases, 
stimulating Tcells, and binding HDL.[56] An additional circulating risk factor associated with 
increased risk of coronary events and strokes is the amino acid, homocysteine, which is a 
byproduct of meat consumption and high circulating levels are also associated with low levels of 
vitamins B6, -12, folate, and renal disease.[57, 58] Studies in the general population have 
determined homocysteine a risk factor of atherogenesis independent of other coronary risk 
factors, but may not be a cause of CVD.[58, 59] 
1.4.1 Adipokines 
In addition, adipocytes produce cytokines termed adipokines, two of which include leptin 
and adiponectin.  These two adipokines in particular may also participate or lend to development 
of CVD.  Adiponectin is anti-atherogenic, anti-inflammatory, and anti-diabetic adipokine, which 
inversely correlates with CVD and obesity and may have a protective role against cardiac 
hypertrophy, hypertenstion, hypertrophic cardiomyopathy, and ischemic heart disease.[17]  
Adipocyte secretion of adiponectin is suppressed in circulation of obese patients and in diabetic 
states affecting the liver, insulin sensitivity, and whole body metabolism. [60] In vivo murine 
models have shown inhibition of adiponectin during systemic inflammation.[61]  Adiponectin 
levels are sensitive serum marker for future CV events even after controlling for traditional CV 
risk factors.[62].  
Leptin is responsible for controlling energy expenditure and increases sympathetic 
activity to CV-relevant organs including the kidneys and adrenal gland potentially predisposing 
an individual to obesity related hypertension.[17]  Circulating leptin levels correspond to obesity 
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and high levels of circulating CRP.[63]  Leptin affects the Th1 immune response[64] and is 
associated with the development of atherosclerosis independent of insulin.[65] 
In general, circulating pro-inflammatory markers increase and anti-inflammatory markers 
decrease with an increase in fat mass and in particular the visceral adipose depot  
1.5 SYSTEMIC LUPUS ERYTHEMATOSUS AND CARDIOVASCULAR DISEASE 
Systemic Lupus Erythematosus (SLE or lupus) is an autoimmune disease associated with 
chronic systemic inflammation.  SLE is more common in women than in men usually 
exacerbated during the early child-bearing years.  All tissue types are susceptible to an 
autoimmune complication and symptoms of SLE vary from person to person.   The disease is 
controlled through a myriad of medications including corticosteroids, immune suppressants, anti-
malarials, and non-steroidal anti-inflammatory drugs (NSAIDS). Currently, there is no cure for 
SLE. There exists a bimodal mortality pattern in the SLE population with an early peak due to 
active disease or SLE-complications and a later peak attributed to atherosclerosis and CVD.[66] 
New treatment methods and earlier diagnoses has significantly improved survival rates within 
the first 5 years of diagnosis to over 90% in the 1990s[67]; however, the later peak due to 
exacerbated and premature CVD is proving to be difficult for the SLE population.  In particular, 
young women with SLE aged 35-44 are over 50 times more likely to experience an MI when 
compared to women without SLE from the Framingham Offspring Study.[68, 69]  Women with 
SLE may also have more vulnerable plaques.  When compared to those without SLE, there is no 
difference in rates of coronary stenosis or total occlusion for those undergoing coronary 
revascularization.  Conversely, cardiovascular outcomes at one year following the coronary 
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revascularization procedure, SLE women have a higher risk of MI and need of a repeat 
percutaneous coronary intervention even after adjusting for CV covariates. [70, 71] 
The risk of hospitalization due to congestive heart failure (CHF) is also increased in SLE 
women aged 18-44years (>2.5 times) along with a 3.5 fold increased risk of mortality than the 
general population with CHF.[71, 72]  Hypertension is also more common in women with SLE 
than the general population and is a univariate predictor of mortality and vascular events in 
SLE.[73-75]  Traditional CVD risk factors within the general population include age, gender, 
smoking, HTN, hypercholesterolemia, diabetes, body composition in particular visceral adipose, 
insulin resistance, circulating hsCRP, and physical inactivity.  For SLE, traditional risk factors 
do not account for the substantial increase in risk associated with MI and stroke at such an early 
age.  Many of the traditional risk factors may be present, but SLE patients are most likely at 
increased risk due to some SLE-specific manifestation. The most obvious additional risk factor is 
the total inflammatory burden due to the chronic inflammation associated with SLE and also 
with atherosclerosis.[73-75] 
Many circulating inflammatory markers associated with excess adipose tissue and 
atherosclerosis are also elevated in SLE patients when compared to the general population.  CRP 
has been an associated risk factor for increased subclinical carotid plaque and IMT [76] along 
with increased coronary artery calcification (CAC) in SLE patients.[77-79] Soluble ICAM-1 has 
also been associated with an increase in CAC in sle patients. [77]  Complement activation by 
immune complexes containing autoantibodies increases tissue inflammation/damage in SLE.[80]  
High levels of circulating complement protein C3 have been associated with greater CVD risk in 
both the general and SLE populations.[81]  High C3 levels are also predictive of CAC [82] and 
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associated with plaque progression and aortic stiffness  [79, 81] along with an increased waist 
circumference, postprandial lipemia, metabolic syndrome [83] 
In addition to these elevated inflammatory components, SLE patients may be more likely 
to have dyslipidemia, [78, 84] and those with dyslipidemia have increased risk of vascular 
events.[68, 73] Other pro-CVD conditions within the SLE population include a pro-
inflammatory form of HDL (iHDL) losing the benefit of having a higher HDL level [80], 
premature menopause thus losing the cardioprotective benefits [85], having hyperhomocystemia, 
which is associated with thrombosis, stroke, and increased CAC in SLE patients [86, 87], having 
hypertension and suffering from high BP (>130mmHg) [78], and an increased risk of developing 
diabetes and insulin resistance.[88, 89]  SLE patients are also more likely to have metabolic 
syndrome than healthy counterparts.[90] Metabolic syndrome as defined by the American Heart 
Association includes a combination of factors including abdominal obesity, dyslipidemia, 
hypertension, insulin resistance, and when taken together has a much greater risk of CVD than 
individually.[4] The metabolically active visceral adipose of abdominal obesity and its 
inflammatory secretions including CRP, IL-6, TNFα, VEGF, PAI-1, angiotensinogen is the 
defining characteristic of metabolic syndrome.[40, 91] 
Not all adipose depots confer the same CVD risk as visceral adipose.  Evaluation of body 
fat distribution and not necessarily overall adiposity is essential when evaluating a CVD risk 
panel.  Excess fat within the abdominal region is associated with pro-inflammatory and 
prothrombotic states along with metabolic syndrome thus increasing the risk of CVD.[92-94] 
Abdominal fat is a surrogate measure of visceral adipose [95] which drains directly into 
the portal vein to be received by the liver thus increasing the upregulation of inflammatory 
cytokines produced by the liver.  Simple weight measures and BMI calculations do not capture 
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adipose distribution or distinguish between fat and fat-free mass.  Body composition is a 
univariate risk factor for atherosclerotic events and an SLE-forced sedentary lifestyle may play a 
role in excess adipose in the SLE population.[75]  SLE patients develop sarcopenic obesity with 
a reduction in muscle mass and over fat more frequently than rheumatoid arthritis patients and 
the general population.[96]  This loss of muscle mass is likely due to physical inactivity and may 
be associated with high dose steroid use.  Steroids inhibit protein synthesis and stimulate protein 
degradation in skeletal muscle.  Body composition changes including a decline in fat free mass 
and bone mineral density and concomitant increase in fat mass occur occurs with age and 
menopause, which also occurs prematurely in the SLE population.  In addition, the systemic 
inflammatory nature of lupus may prove to be an additional risk factor for altered body 
composition.[97]  Furthermore, high levels of circulating inflammatory markers such as TNF α 
have been associated with loss of lean mass in RA patients, which may prove similar in SLE 
patients. [98] 
Some additional CVD risk factors specific to SLE patients include the development of 
renal disease and lupus nephritis.  Serum creatinine levels are independent predictors of IMT 
progression.[81, 87] Other issues with SLE patients that may complicate the CVD burden and 
inflammatory processes include complement deficiency, antiphospholipid antibodies, mannose 
binding protein gene complications, microalbuminuria, neuropsychiatric disease, and 
vasculitis.[99]  Generally, SLE patients have a greater number of traditional CVD risk factors, 
but the same Framingham risk scores suggesting that the traditional risk factors have more 
influence within the SLE population and there may also be differences among SLE patients.[99] 
As mentioned, the traditional risk factors cannot account for the exacerbated CV risk in SLE 
population.  There is still almost an 8 fold increase in occurrence of MI or stroke in SLE after 
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controlling for all traditional risk factors [72]  indicating the influence of some SLE-related risk 
remaining.  With this in mind, it may be just as important to try and treat the known traditional 
risk factors as well through lifestyle changes or medication.[80]  Evaluation of subclinical CVD 
is an important method of determining risk and establish a baseline for CVD intervention 
protocols. 
1.6 SUBCLINICAL CARDIOVASCULAR DISEASE MEASURES 
Subclinical CVD measures are non-invasive risk assessments providing a baseline from 
which to provide the best possible health intervention for reducing CVD risk.  Atherosclerosis is 
a systemic disease with a strong correlation between atheroma found in the carotid and the 
presence of atheroma in the coronary. Numerous subclinical disease measures exist and include 
markers of arterial structure (IMT, plaque presence, calcification) and markers of arterial 
function (EC dysfunction, pulse wave velocity).  Carotid ultrasounds can provide intima media 
thickness, adventitial diameter, and lumen diameter measures along with assessing plaque 
presence.  Greater IMT thickness in the general population is associated with increased risk of 
stroke and MI in both men and women without a history of CVD.[100, 101] SLE patients have a 
significantly higher prevalence of carotid plaque when compared to controls.  Older age at 
diagnosis, longer duration of SLE, and higher homocysteine concentration are independently 
related to atherosclerosis progression within the SLE population.[102] 
Electron beam computed tomography (EBCT) is used to measure coronary calcification 
and aortic calcification.  EBCT is a sensitive and specific marker in the general population and 
produces rapid images without the use of contrast media giving an accurate visualization of the 
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vasculature.  Vascular calcification involves biomineralization through bone metabolism and 
occurs in the intima and media.[103]  Intimal calcification is due to atherosclerosis where medial 
calcification is independent of atherosclerosis and called Monckeberg slcerosis.  Atherosclerosis 
and calcification are more common at bifurcations and those with diabetes mellitus have both 
intimal and medial calcification.  Hypertension is a known risk factor for atherosclerosis and 
distal aortic calcification, which increases vascular rigidity and the hemodynamics of blood 
flow.[103]   
SLE patients have diffuse calcification over several vascular beds when compared to age 
and gender matched controls and the extent of calcification is also greater in SLE vs 
control.[104]  CAC has been a better predictor of future CV events than thoracic aorta 
calcification. CAC is a marker of subclinical atherosclerosis strongly associated with CHD and 
mortality [105] CAC is more frequent in SLE than controls and the mean artery calcification 
score is significantly higher in patients when compared to healthy controls independent of 
traditional risk factors.[77]   
Use of subclinical CVD measures and lupus – specific disease control methods through 
lifestyle changes and medications will relieve the overall cumulative burden of inflammation.  
The SLE-specific CVD risk factors still remain to be determined in order to develop improved 
treatment options.  Smaller visceral adipose depots are receiving increased attention for their 
localized inflammatory role in cardiovascular disease.  Mouse models have shown extensive 
complement protein deposition throughout the perivascular adipose tissue (PVAT) surrounding 
the descending thoracic aorta and bound to the ECM constituents of the vascular wall including 
collagen and elastin.  We hypothesized that the PVAT surrounding the descending thoracic aorta 
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of lupus patients would be greater when compared to healthy controls and this difference would 
be associated with the increased coronary and aortic calcification of the SLE population. 
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2.0  METHODS 
2.1 INCLUSION / EXCLUSION CRITERIA 
A retrospective case-control study was performed on SLE participants and their 
respective 1:1 matched age and race controls.  Women who fulfilled the 1987 revised American 
College of Rheumatology criteria of SLE[73] but with no prior history of cardiovascular event 
were non-selectively recruited from the Pittsburgh Lupus Registry to participate in the SLE 
study, which was designed to compare the prevalence and risk factors of coronary artery and 
aortic calcification in SLE women and healthy controls.  These women were participating in the 
“Heart Effects on Atherosclerosis and Risk of Thrombosis in SLE” (HEARTS) study. 
SLE women had at least 2 years of disease duration. This lupus registry includes women 
diagnosed with SLE who have been seen either at the UPMC inpatient and outpatient facilities or 
by practicing rheumatologists in the Pittsburgh metropolitan area. In this study, the healthy 
women (controls) were matched to the SLE women by age (+/- 5 years) and race. The 
recruitment methods for healthy controls were based on the following: 1) Voters registration list 
or Motor Vehicle License list depending on where the case (SLE woman) was found in these 
lists; 2) direct sample neighborhood control if the case was not in the previous lists. (SLE, 
n=161; Control, n=161) 
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Subjects with diabetes mellitus, as defined by history of diabetes or fasting glucose ≥7 
mmol/L (≥126 mg/dL) or hypoglycemic therapy, (SLE, n=8; Control, n=3) were excluded. 
2.2 DATA COLLECTION/MEASURES 
Information on patient demographics and potential risk factors was collected at the time 
of Electron Beam Computed Tomography (EBT) scan. The University of Pittsburgh Institutional 
Review Board approved these studies; all patients gave written informed consent. The study visit 
included anthropomorphic measurements (height, weight, and waist and hip circumferences), 
two consecutive blood pressure readings (with patients seated), and a blood draw after a required 
fast, which was uniform between groups. Blood samples were used to measure total cholesterol, 
triglycerides, and high-density lipoprotein (HDL) cholesterol at the Lipid Laboratory in the 
University of Pittsburgh, Graduate School of Public Health, which has been certified by the 
Centers for Disease Control and Prevention. Low-density lipoprotein (LDL) cholesterol was 
calculated from measured total cholesterol, HDL and triglycerides (Friedewald equation).[106] 
Metabolic syndrome was defined by the National Cholesterol Education Program Adults 
Treatment Panel III guidelines.[107] The homeostatic model assessment of insulin resistance 
(HOMA-IR) was calculated by [insulin (mU/liter) × glucose (mmoles/Liter)] ÷22.5.[108, 109] 
Hypertension was defined by physician diagnosis, measured mean blood pressure ≥140/90 mm 
Hg or antihypertensive medication use. Other information was collected on family history of 
ASCVD (first-degree relative having myocardial infarction or stroke before age 60), cigarette 
smoking (current, past, or never), and menopausal status. Information was recorded on 
corticosteroid treatment (current use, ever used, and daily dosage) and current use of 
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hydroxychloroquine, immunosuppressants for SLE or other disease modifying anti-rheumatic 
drugs, non-steroidal anti-inflammatory drugs, antihypertensives, hormonal therapy, and lipid-
lowering medications.  
Fibrinogen was measured using a modified clot-rate assay. An enzyme-linked 
immunosorbent assay was used for determination of high sensitivity CRP (hsCRP). sICAM-1 
was measured using commercial assays (Parameter Human sICAM-1 Immunoassay; R&D 
Systems, Minneapolis, MN) at the Laboratory for Clinical Biochemistry Research (University of 
Vermont, Burlington, VT). 
2.3 EBT SCANS 
The EBT scans were performed using an Imatron C-150 scanner (Imatron, San Francisco, 
CA) using standard imaging procedures in all participants. The same scanner and methodology 
was used in the SLE and healthy controls. For CAC, 3-mm slices were scanned at the same point 
in diastole (at 80% of the patient's RR interval in electrocardiogram) during a single breath hold, 
starting at the aortic root to the apex of the heart. Following completion of the coronary scan, 
aortic scans (6mm transaxial images, 300 ms exposure time) were obtained from the aortic arch 
to the iliac bifurcation. All scan data was saved to optical disc and scoring of calcification 
(Agatston and volumetric) was performed using a DICOM work station and software by 
AcuImage. The individual region of interest scores were then summed for a total Agatston 
calcification score.[110]  The analysis was based on the total Agatston calcification scores as 
previously described.[111]  The participants’ EBT scans for PVAT quantification that were not 
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included were due to missing files on the optical disk, bad optical disks, and perhaps being 
miscatalogued (n=24: nSLE=18, nControl=6). 
2.4 PERIVASCULAR ADIPOSE TISSUE VOLUME 
The 6mm transaxial EBT images were used to quantify the PVAT surrounding the 
descending thoracic aorta using the commercially available software (Slice-O-Matic, 
Tomovision, Montreal, Canada).  The aortic PVAT was distinguished from the remaining tissue 
using physiological landmarks.  The posterior border is the anterior portion of the vertebral 
foramen.  The anterior border and left/right lateral borders change as the images progress distally 
from the carina and includes the left bronchus, esophagus, and crus of diaphragm.  The first 
proximal image analyzed includes the carina also known as the pulmonary bifurcation and each 
6mm image is quantified through vertebral body, T12.  Analysis stops at the pedicles of 
L1.(Figure 1)  Adipose tissue areas were calculated by the range of attenuation values for 
Figure 1: Sample EBCT scan with yellow 
boundary and red adipose. 
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adipose (–190 to –30 HU) tissue.  A volume was calculated by summing the areas and 
multiplying by the length of the participant’s aorta.  A reproducibility analysis was conducted for 
the quantification of PVAT volume and excellent intra- and inter-reader reproducibility for the 
measurement of thoracic PVAT (intra-class correlation coefficient 0.999 and 0.998, respectively) 
was demonstrated in a random subset of participants. 
2.5 OUTCOMES 
Total aortic PVAT (tPVAT) volume along the length of the thoracic aorta was evaluated 
with traditional CVD risk factors and inflammatory factors associated with SLE.  The PVAT 
volume was also evaluated against valid subclinical CVD measures including aortic calcification 
(AC) and coronary artery calcification (CAC).  The contribution of tPVAT to vascular 
calcification including AC and CAC along with adjustments for CVD risk factors and circulating 
inflammatory markers was also evaluated. 
Predictor variables included traditional CVD risk factors: smoking history, average 
systolic blood pressure (SBP), postmenopausal status, hypertension, log transformed HOMA-IR, 
cholesterol ratio (total cholesterol/high density lipoprotein cholesterol), and homocysteine serum 
levels.  Inflammatory risk factors included log transformed C-reactive protein (logCRP) and log 
transformed plasminogen activating inhibitor (logPAI) along with serum levels of fibrinogen, 
intercellular adhesion molecule (sICAM) and eSelectin.  Additional adjustments were made for 
BMI and metabolic syndrome.   
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2.6 STATISTICAL ANALYSIS 
Descriptive statistics were calculated for demographic variables, cardio-metabolic 
factors, subclinical CVD measures including CAC and AC, and PVAT volume total.  
Differences between SLE and control outcomes were assessed with either t-tests or Mann-
Whitney U tests for continuous covariates and chi square or Fisher’s exact test for categorical 
variables.  Spearman correlations were used to assess associations between cardio-metabolic 
factors, outcome (SLE vs control), tPVAT volume, and log transformed CAC and AC.   
A multivariate linear regression was used to determine the CVD risk factors and 
circulating inflammatory risk factors that influenced tPVAT volume and this analysis was 
stratified by disease status.  The models were developed with adjustment for predetermined CVD 
risk factors (history of smoking, postmenopausal status, hypertension, log HOMAIR, cholesterol 
ratio (total cholesterol/hdl) homocysteine and average systolic blood pressure) and inflammatory 
factors (log PAI, log CRP, fibrinogen, sICAM, and eselectin).   
Logistic regression was used to determine the association between tPVAT, CAC, and AC 
with SLE.  The association of tPVAT with SLE was evaluated with the control group being 
referent.  The models were adjusted for predetermined CVD risk factors and inflammatory 
factors with the control group being referent.  In a separate set of models, logistic regression was 
used to determine the contribution of tPVAT along with CVD risk factors and circulating 
inflammatory markers to any vascular calcification, AC or CAC separately.  All analyses were 
performed using SAS (version 9.2, SAS Institute, Cary, North Carolina).  The level of statistical 
significance was set at a 2-sided p-value of 0.05. 
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2.6.1 Reproducibility Analysis 
Eleven (n=11) HEARTS participants were chosen at random to determine the 
reproducibility of the EBCT scan reading protocol quantifying the PVAT of the descending 
thoracic aorta.  Two readers (MG and KJS) were given the protocol and the EBCT scans of the 
11 participants.  Two separate readings were completed approximately 3 to 4 weeks apart to 
determine intra- and inter-reader variability.  Spearman correlations, linear regression, 
descriptive difference statistics, intra-class correlations, and Bland-Altman plots were used to 
determine consistency, variability, and systematic bias.  
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3.0 RESULTS 
3.1 DEMOGRAPHICS 
The characteristics of the study groups are summarized in Table 1.  The SLE and control 
groups were comparable among many covariates including age, BMI, ethnicity, smoking status, 
metabolic syndrome prevalence, systolic and diastolic blood pressures, insulin and HOMA-IR.   
Women with SLE were slightly more likely to be postmenopausal than healthy controls 
(p=0.058) and more likely to be hypertensive (p<0.0001).  The SLE group had lower pulse 
pressures (p=0.0049) partially explained due to blood pressure (BP) lowering medications to 
control hypertension.  In addition, the SLE group had lower serum glucose levels (p<0.0001), 
total cholesterol (p=0.0027) and LDLc (p=0.0009) when compared to their healthy controls.  
Lower glucose levels for SLE women versus controls persisted when subjects with diabetes were 
excluded from the analysis.  Likewise, significant group differences in lipid profiles persisted 
after controlling for lipid lowering medications.  Despite the exclusion of diabetics from the 
analysis the differences in glucose could not be explained.  More of the SLE group was on lipid 
lowering medications (p=0.044), but that did not fully explain the differences in lipid panel.  As 
expected, several inflammatory factors including CRP, PAI, sICAM, cd40, eSelectin, albumin, 
and homocysteine were significantly greater in the SLE study group.  There were no control 
group measurements for complement C3 and C4 serum levels for group comparisons. 
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Table 1: Demographic, clinical, and laboratory characteristics of SLE participants and controls.  
Covariates SLE 
(n=153) 
Control  
(n=158) 
p-value 
Age (yr) 49.5 (9.7) 51.1 (9.7) 0.14 
Caucasian, n (%) 134 (87.6%) 143 (90.5%) 0.41 
Current Smoker, n (%) 16 (10.5%) 20 (12.7%) 0.54 
Post menopausal Status, n(%) 90 (58.5%) 76 (48.1%) 0.058 
BMI (kg/m2) 27.0(22.6 - 31.9) 26.9 (23.8 - 32.1 0.26 
Metabolic Syndrome 39(25%) 29(31%) 0.17 
Waist Circumference (cm) 83(75-94.5) 81.5 (73 -93) 0.46 
Waist to Hip Ratio 0.833(0.79-0.88) 0.797(0.77-0.84) 0.001 
SBP (mm Hg) 119(106-132) 120 (110-135) 0.087 
DBP (mm Hg) 76.6(10.3) 76.2 (9.84) 0.71 
pulse pressure 41(35-50) 45.8(37.5-59) 0.0049 
Hypertensive  82(54%) 48(31%) <0.0001 
Glucose (mmol/L) 89 (82-94) 93 (88-101) <0.0001 
Insulin (pmol/L) 12.1 (9.1-17.6) 11.4 (9.2-14.8) 0.29 
HOMA-IR (mmol/L x µU/mL)# 7.01(4.9-10) 6.66(5.4-9.4) 0.88 
LIPID PANEL    
Triglycerides (mmol/L) 111 (76-153) 103 (74-140) 0.14 
Total Cholesterol (mmol/L) 185 (162-215) 203 (175-222) 0.0027 
HDLc (mmol/L) 54.2 (43.1-62) 56 (46.4-63.8) 0.12 
LDLc (mmol/L) 107 (87-107) 121 (101-141) 0.0009 
Cholesterol Ratio (tot cho/hdl) 1.23 (1.1-1.4) 1.27 (1.1-1.5) 0.85 
INFLAMMATORY FACTORS    
CRP (mg/L)  2.34 (0.93-5.5) 1.61 (0.61-3.6) 0.032 
Fibrinogen (mg/dL) 337.4 (86.1) 344.7 (63.0) 0.4 
PAI (ng/ml)  15.7 (9.6-28) 11.8 (6.0-25.4) 0.016 
sICAM (ng/ml)  265 (233-319) 245 (212-276) <0.0001 
cd40 ligand  5543 (3759-7822) 6205 (4804-8136 0.012 
eSelectin (ng/ml) 47.1 (31.2-62.8) 36.6 (26.4-53.2) 0.0009 
Albumin (g/dL) 4.6 (4.2-4.9) 4.3 (4-4.6) <0.0001 
Homocysteine (µmol/L) 9.7 (8-11.8) 8.9 (7.6-10.3) 0.0088 
C3 96 (82-118) N/A  
C4 19 (15-25) N/A  
MEDICATIONS    
NSAID 59 (38.6%) 21 (13.3%) <0.0001 
Aspirin 20 (13.1%) 13 (8.23%) 0.17 
Hormone Replacement Therapy 20 (13.1%) 19 (12.0%) 0.78 
Lipid Lowering Medication,n (%) 13 (8.5%) 5 (3.2%) 0.044 
Corticosteroids 63 (41.2%) 0 <0.0001 
years on prednisone (n=59) 12(7-18) N/A  
Immunosuppressant 27 (17.7%) 0 <0.0001 
Plaquenil 71 (46.4%) 0 <0.0001 
Family History MI <60yo 62(41%) 48 (31%) 0.071 
Family History Stroke <60yo 35 (23%) 18 (12.0%) 0.0074 
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There was a significant difference between the SLE (median (25%-75%): 3.293 (1.39-
5.46)) and control (1.946(0.00-4.28)) group in mean log aorta calcification score (p=0.0013) and 
a mild association with mean log coronary calcification score (SLE: (0.000(0.00-2.74)) and  
A. 
 
B. 
 
Figure 2:  Presence of vascular calcification between SLE and Control groups, (chi square p-value). 
 A) Aortic Calcification, Chi Square, (p=0.0008), B) Coronary Artery Calcification, (p=0.20). 
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control: (0.000(0.00-1.45)), p=0.086) exists.  When evaluating the presence of calcification using 
the chi square test, there is a preference for the SLE group to have AC (p=0.0008), but there is 
not a strong preference with CAC (p=0.20).(Figure 2)  The SLE group was more likely to have a 
family history of stroke prior to 60 years old (p=0.0074) and slightly more likely to have a 
family history of MI prior to 60 years old (p=0.071). 
3.2 TOTAL PERIVASCULAR ADIPOSE VOLUME 
The SLE (median (25-75%): 32.2 (25-42) cm3) group had greater total PVAT (tPVAT, 
p=0.0071) than controls (28.6 (22-37) cm3) with more SLE participants having higher tPVAT 
volumes.(Figure 3)  There were no differences between the SLE group and controls in the 
participants’ overall height or the length of the aorta.(not shown)  Overall tPVAT was 
significantly correlated with all selected CVD risk factors and inflammatory factors regardless of 
SLE status.(Table 2)  This was true within SLE and control groups except for homocysteine, 
sICAM, and eSelectin in the SLE group.(Table 2)   
Logistic Regression 
 In a univariate logistic regression model, tPVAT alone was associated with SLE (1.019 
[1.00-1.034], p=0.020).  The tPVAT odds ratio (OR) associated with SLE remained significant 
when adjusting for CVD risk factors (1.022[1.0-1.04], p=0.035) and became non-significant 
when adjusting for inflammatory factors (p=0.34). 
The model was expanded to include obesity-related factors BMI, metabolic syndrome 
(MS) or metabolic syndrome components (MSc: triglyceride, HDL, and glucose levels, waist to 
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hip ratio, and average systolic blood pressure) along with appropriate CVD risk factors 
(hypertension, homocysteine serum levels, average systolic blood pressure, history of smoking, 
postmenopausal status, log HOMA-IR, and the cholesterol ratio) and inflammatory factors  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3:  Total PVAT distribution for A) SLE; B) controls. (p=0.0071).  Dash indicates median values. 
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(fibrinogen, sICAM, log CRP, log PAI and eSelectin) dependent on the obesity-related factor 
used thus ensuring not to have adjustment overlap.  When evaluating BMI the CVD risk factors  
Since the MS diagnosis included: history of smoking, postmenopausal status, 
hypertension, homocysteine, HOMAIR (log), cholesterol ratio, average SBP, and waist to hip 
ratio.  includes some of the CVD risk factors, when evaluating the MS influence the CVD risk 
factors included: history of smoking, postmenopausal status, hypertension, and homocysteine.  
Lastly, when evaluating the components of an MS (MSc) diagnosis, the CVD risk factors 
included: history of smoking, postmenopausal status, hypertension, homocysteine, and log 
HOMAIR. 
Table 2:  Spearman correlations between Total PVAT with clinical and laboratory outcomes, rho(p-value). 
Covariate 
SLE  
tPVAT 
Control  
tPVAT 
Overall  
tPVAT 
HOMA-IR 0.384(<0.0001) 0.422(<0.0001) 0.401(<0.0001) 
SBP 0.300(0.0004) 0.427(<0.0001) 0.342(<0.0001) 
cholesterol ratio 0.178(0.039) 0.216(0.0075) 0.191(0.0012) 
Homocysteine 0.164(0.057) 0.170(0.036) 0.192(<0.009) 
PAI 0.285(0.0008) 0.360(<0.0001) 0.348(<0.0001) 
Fibrinogen 0.191(0.026) 0.221(0.0072) 0.197(<0.0009) 
sICAM 0.130(0.13) 0.354(<0.0001) 0.269(<0.0001) 
eSelectin 0.154(0.076) 0.276(0.0006) 0.230(<0.0001) 
C3 0.215(0.013) N/A 0.215(0.013) 
CRP 0.382(<0.0001) 0.373(<0.0001) 0.404(<0.0001) 
BMI 0.518(<0.0001) 0.572(<0.0001) 0.531(<0.0001) 
Metabolic Syndrome Score 0.425(<0.0001) 0.547(<0.0001) 0.507(<0.0001) 
waist to hip ratio 0.327(0.0001) 0.228(0.0048) 0.303(<0.0001) 
 
The tPVAT remained significantly associated with SLE outcome when evaluated with 
BMI alone (tPVAT, p=0.0038) and MS components alone (tPVAT, p=0.0079).  Both the BMI 
(0.993[0.91-0.995],p=0.030) and the glucose (0.933[0.91-0.96],p<0.0001) of the MSc were 
protective against SLE.  The tPVAT association with SLE evaluating MS alone was attenuated 
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to non-significance (p=0.059) while MS was also not a significant obesity-related factor 
(p=0.59).  Measures of adiposity such as BMI do not describe adipose distribution accurately.  
The waist to hip ratio is another anthropomorphic measure, which takes into consideration the 
distribution of adipose.  When tPVAT was evaluated with the waist to hip ratio alone, the tPVAT 
was slightly attenuated but still significant (1.016[1.0-1.03],p=0.044); however, the waist to hip 
ratio itself was not significantly associated with SLE (p=0.18). 
The tPVAT (p=0.022) remained significantly associated with SLE when evaluated with 
the BMI (p=0.31) and CVD risk factors; however, tPVAT (p=0.13) did not remain significant 
when evaluated with BMI (p=0.0022) and inflammatory risk factors.  The tPVAT (p=0.17) did 
not remain significantly associated with SLE when evaluated with MS (p=0.50) and CVD risk 
factors or with inflammatory factors (tPVAT (p=0.33) and MS (p=0.28)).  The tPVAT (p=0.065) 
was slightly attenuated to non-significance with MS components and both the CVD and 
inflammatory risk factors. (Table 3)  The tPVAT (p=0.16) loses the significant association with 
SLE when evaluated with waist to hip ratio (p=0.24) and the CVD risk factors.  This loss of 
significance trend continues of tPVAT (p=0.42) with waist to hip ratio (p=0.18) and 
inflammatory risk factors. 
MV Linear Regression 
Multivariate linear regression was used to determine the significant CVD and 
inflammatory risk factors affecting the tPVAT with significance held at p<0.25 level.  The waist 
to hip ratio was included with the obesity-related factor BMI to include an adipose distribution 
factor, which is taken into consideration with MS.  The CVD risk factors that affect log tPVAT 
volume for SLE patients include BMI (0.0302± 0.0054,p<0.0001), postmenopausal status 
(0.208±0.066, p=0.0019), and waist to hip ratio (0.6173±0.34,p=0.073) were significant, while 
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the CVD risk factors for controls included BMI (0.0196±0.0046,p<.0001), history of smoking 
(0.103 ±0.051,p=0.046), postmenopausal status (0.184±0.055,p=0.0010), logHOMAIR 
(0.115±0.065, p=0.077), and average SBP ( 0.00315± 0.0016, p=0.056).  Evaluating the 
inflammatory factors alone within the SLE population log PAI-1 (0.0582±0.044,p=0.19) and log 
CRP (0.115±0.031, p= 0.0003) are significant, while for controls, log PAI-1 (0.108±0.033, p= 
0.0012), log CRP(0.0874±0.025, p=0.0007), and sICAM (0.000611±0.00040, p= 0.13) are 
significant.  The same sequence of analyses with MS instead of BMI show that CVD risk factors 
for SLE include, MS (0.311±0.057, p=0.0001) and postmenopausal status 
(0.222±0.070,p=0.0018) significantly affect log tPVAT while for the controls, MS 
(0.385±0.078,p<0.0001), history of smoking (0.145±0.053, p=0.0075), postmenopausal status 
(0.158±0.057, p=0.0063) and hypertension (0.0812±0.067, p=0.23) significantly affect log 
tPVAT.  Metabolic syndrome with inflammatory factors for SLE include MS (0.284±0.087, 
p=0.0014), log CRP (0.119±0.030, p=0.0001), and sICAM (-0.000777±0.00044, p=0.087) while 
for controls include MS(0.290±0.082, p=0.0006), log CRP (0.0626±0.025, p=0.015) and log 
PAI-1 (0.0899±0.032, p=0.0054). 
Table 3:  Logistic regression of total PVAT association with outcome status (SLE).   
Cardiovascular risk factors: CVD, Inflammatory risk factors: Inflam, Metabolic Syndrome: MS, 
Components of Metabolic Syndrome: MSc 
 
 
Risk of SLE  
OR(95% Confidence Interval) p-value 
Model 1:  
tPVAT + CVD 
tPVAT + Inflam 
1.022 (1.00-1.04) 
1.007(0.99-1.02) 
0.034 
0.34 
Model 2:  
tPVAT + CVD + BMI 
tPVAT +CVD+MS 
tPVAT + CVD + MSc 
 
1.025 (1.00-1.05) 
1.013(0.99-1.03) 
1.016 (0.99-1.03) 
 
0.022 
0.17 
0.065 
Model 3:  
tPVAT + Inflam + BMI 
tPVAT +Inflam+MS 
tPVAT + Inflam + MSc 
 
1.014(0.99-1.03) 
1.01 (0.99-1.02) 
1.016 (0.99-1.03) 
 
0.13 
0.33 
0.065 
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Considering all factors with BMI, the significant covariates for the SLE group included 
BMI (0.0261±0.0061, p<0.0001), postmenopausal status (0.197±0.067, p=0.0037), waist to hip 
ratio (0.545±0.35, p=0.12), and log CRP (0.0443±0.031, p=0.15) while the control group 
included postmenopausal status (0.202±0.054, p=0.0003), log CRP (0.0579±0.023, p=0.014), 
BMI (0.0172±0.0049, p=0.014), history of smoking (0.0969±0.051, p=0.057), log HOMAIR 
(0.0791±0.065,p=0.23), and average SBP (0.00320±0.0017,p=0.054).  Considering all factors 
with MS, the significant covariates for the SLE group include MS (0.298±0.085,p=0.0006), 
postmenopausal status (0.201±0.069,p=0.0041), log CRP (0.107±0.029,p=0.0004), and sICAM 
(-0.000874±0.00043,p=0.044) while those significant for the control group include MS 
(0.220±0.086,p=0.012), history of smoking (0.114±0.054,p=0.037), postmenopausal status 
(0.169±0.056,p=0.0032), hypertensive status (0.0848±0.067,p=0.20), log CRP 
(0.0696±0.024,p=0.0047) and log PAI-1 (0.0634±0.031,p=0.042).  No interactions between the 
significant CVD or inflammatory risk factors and group were detected.  (Table 4) 
Table 4:  Multivariate Linear Regression covariate results per obesity-related factors and outcome.  
Forward selection, p<0.25. 
 
BMI MS 
SLE  
tPVAT 
Control  
tPVAT 
SLE  
tPVAT 
Control  
tPVAT 
BMI  
0.0261±0.0061, p<0.0001 
BMI 
0.0172±0.0049, p=0.014 
MS 
0.298±0.085,p=0.0006 
MS 
0.220±0.086,p=0.012 
Postmenopausal Status 
0.197±0.067, p=0.0037 
Postmenopausal Status 
0.202±0.054, p=0.0003 
Postmenopausal Status 
0.201±0.069,p=0.0041 
Postmenopausal Status 
0.169±0.056,p=0.0032 
log CRP 
0.0443±0.031, p=0.15 
log CRP 
0.0579±0.023, p=0.014 
logCRP 
0.107±0.029,p=0.0004 
logCRP 
0.0696±0.024,p=0.0047 
waist to hip ratio 
0.545±0.35, p=0.12 
History of smoking 
0.0969±0.051, p=0.057 
sICAM 
-0.00087±0.0004,p=0.044 
History of Smoking 
0.114±0.054,p=0.037 
 logHOMAIR 
0.0791±0.065,p=0.23 
 logPAI-1 
0.0634±0.031,p=0.042 
 avg SBP 
0.00320±0.0017,p=0.054 
 Hypertension 
0.0848±0.067,p=0.20 
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3.3 PVAT AND VASCULAR CALCIFICATION 
Total PVAT is highly correlated with both logCAC(0.441,<0.0001) and logAC 
(0.420,<0.0001).  The correlation of tPVAT is slightly greater in SLE (logCAC: 0.469,<0.0001; 
logAC: 0.418, <0.0001) than in controls (logCAC: 0.406,<0.0001; logAC: 0.384, <0.0001). 
Logistic Regression: SLE / Control on AC and CAC 
In logistic regression analysis, AC alone was associated with SLE by a factor of 2.3 
(95%CI:1.4-3.8, p=0.001).  When adjusting for the CVD risk factors and BMI the OR increases 
to 3.36((1.85- 6.12),p<0.0001) and is slightly attenuated with MS and associated CVD risk 
factors 2.12 ((1.26-3.59),p=0.0049).  When adjusting for BMI and inflammatory factors the AC 
OR is attenuated (2.52 (1.42-4.47),p=0.0015) and even more so with MS and the inflammatory 
factors (1.83 (1.07-3.13)p=0.028). CAC did not show any statistical preference between SLE and 
the control group. 
Logistic Regression:  tPVAT on AC and CAC 
In a logistic regression analysis, tPVAT alone was associated with any AC by a factor of 
1.073 [1.04-1.1] (p<0.0001) (Table 5A) and with any CAC by a factor of 1.051 [1.03-1.07] 
(p<0.0001) (Table 5B).  The model was expanded to include either tPVAT and BMI, MS, or MS 
components (triglyceride, waist to hip ratio, HDL, glucose, and average SBP) and stratified by 
outcome.   
 For the AC, adjusting for CVD and inflammatory risk factors slightly attenuated the 
effect of tPVAT on AC, but remained significant regardless of BMI, MS, or MS components.  
For the CAC, the significant effect of tPVAT on CAC was dependent whether BMI, MS, or MS 
components were used when adjusting for CVD and inflammatory risk factors.  When adjusting 
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for BMI or MS components along with either CVD or inflammatory components, tPVAT did not 
remain a significant effect on CAC.  However, when adjusting for MS alone with either CVD or 
inflammatory risk factors, tPVAT did remain a significant effect on CAC. (Table 5B) 
Interestingly, when stratifying the logistic regression by outcome (SLE vs Control) BMI 
attenuates the influence of tPVAT on both AC and CAC to non-significance within the SLE 
group, but tPVAT remains a significant effect for both AC and CAC in controls. (Table 6A-B)  
The tPVAT remains significant for both SLE and control when controlling for MS with both AC 
and CAC. 
Table 5:  Logistic regression evaluating  A. tPVAT with any AC B. tPVAT with any CAC.   
Cardiovascular risk factors: CVD, Inflammatory risk factors: Inflam, Metabolic Syndrome: MS, 
Components of Metabolic Syndrome: MSc 
A. 
 
Risk of any AC  
OR(95% Confidence Interval) p-value 
Model 1:  
tPVAT 
1.073(1.043- 1.103) <0.0001 
Model 2:  
tPVAT+CVD+BMI 
tPVAT+CVD+MS 
tPVAT+CVD+MSc 
 
1.053(1.02-1.09) 
1.063(1.03-1.1) 
1.049(1.02-1.08) 
 
0.0006 
<0.0001 
0.0037 
Model 3:  
tPVAT + Inflam+BMI 
tPVAT + Inflam + MS 
tPVAT + Inflam + MSc  
 
1.065(1.030-1.1) 
1.061(1.03-1.1) 
1.060(1.02-1.09) 
 
<0.0001 
0.0003 
0.0004 
B. 
 
Risk of any CAC  
OR(95% Confidence Interval) p-value 
Model 1:  
tPVAT 
 
1.051(1.03-1.07) 
 
<0.0001 
Model 2:  
tPVAT +CVD + BMI 
tPVAT + CVD + MS 
tPVAT + CVD + MSc 
 
1.007 (0.99-1.02) 
1.022(1.0-1.04) 
1.016(0.99-1.03) 
 
0.41 
0.046 
0.059 
Model 3:  
tPVAT + Inflam + BMI 
tPVAT +inflam+MS 
tPVAT + Inflam + MSc 
 
1.017 (0.99-1.04) 
1.022(1.00-1.04) 
1.020(0.99-1.04) 
 
0.076 
0.040 
0.068 
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 When adjusting for MS components (MSc) for CAC, the tPVAT of the control group 
remains significant while the tPVAT influence for the SLE group is attenuated to non-
significance.  In addition, when controlling for the MS diagnosis for both AC and CAC in both 
SLE and control, the tPVAT influence on the calcification remains significant and the OR for 
AC is increased.(Table 6A) Also of note, the OR for the MS influence on CAC is 3.13[1.3-7.6] 
(p=0.012) for SLE and 4.73[1.6-14](p=0.0046) for control while there is no significant influence 
of MS on AC for either SLE or controls.(not shown) 
Table 6:  Logistic regression evaluating tPVAT with any AC or any CAC adjusting for  
BMI, MS, or MS components. 
A. 
 
Risk of any AC  
OR(95% Confidence Interval) p-value 
SLE: tPVAT + BMI 1.049(0.99-1.10) 0.065 
Control: tPVAT + BMI 1.044(1.01-1.083) 0.025 
SLE:tPVAT + MS 1.077(1.03-1.13) 0.0036 
Control: tPVAT + MS 1.050(1.01-1.09) 0.012 
SLE: tPVAT + MSc 1.063(1.01-1.12) 0.025 
Control: tPVAT + MSc 1.048(1.009-1.089) 0.016 
B. 
 
Risk of any CAC  
OR(95% Confidence Interval) 
p-value 
SLE: tPVAT + BMI 1.013(0.993-1.033) 0.21 
Control: tPVAT + BMI 1.038(1.01-1.073) 0.024 
SLE:tPVAT + MS  1.030(1.00-1.06) 0.029 
Control: tPVAT + MS 1.040(1.01-1.08) 0.020 
SLE: tPVAT + MSc 1.020(0.99-1.046) 0.13 
Control: tPVAT + MSc 1.037(1.002-1.073) 0.036 
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Complement, Calcification and SLE 
 Only the SLE participants had measures of complement proteins C3 and C4 quantified.  
Spearman correlations showed that C3 (0.215, p=0.013) was correlated to tPVAT and that both 
C3 (0.249, p=0.0023) and C4 (0.221, p=0.0099) were correlated with log CAC, but not with log 
AC.  A univariate linear regression confirmed the association of log C3 (0.282+/-0.14, p=0.043) 
with log tPVAT and the non-significance of log C4 (p=0.37).  
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4.0 DISCUSSION 
This is the first study to compare the unique tPVAT volume surrounding the descending 
thoracic aorta within clinically cardiovascular disease free SLE participants and their age- and 
race-matched, healthy controls.  Women with SLE have increased tPVAT when compared to 
their healthy controls.  The tPVAT is also significantly correlated with cardio-metabolic risk 
factors in both the SLE and control participants.  Total PVAT is independently associated with 
AC regardless of adjustments for CVD risk and inflammatory factors or obesity-related factors, 
while CAC retains significance to tPVAT when CVD risk and inflammatory factors are adjusted 
with MS.  The premature AC in SLE participants regardless of obesity-related factors and CVD 
or inflammatory factors reflects the increased pre-clinical CVD burden for those with SLE. 
Most traditional CVD risk factors and a few SLE-related factors [76, 77, 79] have been 
implicated in the accelerated progression of CVD in the SLE population.  Obesity-related factors 
such as waist to hip ratio are surrogate measures for adipose distribution, which has been found 
to be significantly different between asymptomatic CVD SLE and control groups [99] despite 
limited [112] to no significant differences in BMI.[99]  In this study there were no significant 
differences between BMI, waist circumference, and metabolic syndrome between the SLE and 
control participants.  However, the distribution of adipose was significantly different when 
evaluating the waist to hip ratio (SLE: 0.833 (0.79-0.88), Control: 0.797(0.77-0.84), p=0.001), 
which suggests the importance of evaluating separate and distinct adipose regions. [113]  
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Smaller, visceral adipose depots have been gaining more attention for their localized 
inflammatory role in CVD.  Epicardial adipose is a small, visceral adipose depot found between 
the myocardium and the visceral layer of the pericardium, which can transform from a cardio-
protective state into a pro-inflammatory, pro-thrombotic pathological state.[24]  Strong evidence 
exists in linking excessive epicardial adipose with CVD development and progression. The 
descending thoracic aorta tPVAT is a distinct, small visceral adipose reservoir.  In the 
multivariate linear regression analysis involving all factors, there were similarities and 
differences in CVD risk factors and inflammatory factors associated with the descending thoracic 
aorta tPVAT depending on the obesity-related factor used (BMI or MS) and on the outcome 
(SLE or control).  The obesity-related factor, postmenopausal status, and log CRP were always 
significant regardless of outcome; however, the controls consistently had more significant factors 
including lifestyle or medication modifiable factors such as history of smoking and hypertension.  
In addition, the association of tPVAT to SLE remains significant after adjusting for CVD risk 
factor and BMI.  This significance is lost when adjusting for inflammatory components or with 
the obesity-related factor MS, which is associated with elevated CRP and inflammation.[114]  
The loss of significance of tPVAT to SLE when evaluating inflammatory factors or obesity-
related factors closely associated with inflammation underscores the influence of the 
inflammatory component(s) in SLE.  The increased CV risk of SLE patients along with their 
chronic inflammatory disease state and the fewer number of CVD and inflammatory risk factors 
associated with tPVAT suggests an amplified inflammatory response and perhaps an increased 
dysfunction of the adipose of an SLE patient.   
Adipocyte size and adipose cellular composition including inflammatory infiltrates such 
as mast cells and leukocytes (neutrophils, dendritic cells, lymphocytes and monocytes), 
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macrophages, fibroblasts, adipocytes and preadipocytes are responsible for the normal metabolic 
activity of adipose and the dysfunction of adipose including production of many of the 
circulating inflammatory and atherogenic factors.[17, 115]  These same inflammatory markers 
link obesity, atherosclerosis, and inflammation to SLE resulting in an exacerbated chronic 
inflammatory state.  As noted, not all adipose depots confer the same CVD risk.  In particular, 
excessive visceral adipose tends to upregulate circulating inflammatory components and the 
distribution of adipose becomes more important than overall adiposity.  SLE patients tend to 
develop a loss of muscle mass and fat free mass with a concomitant increase in fat mass.  This 
altered macro body composition also extends to the tPVAT of the descending thoracic aorta, 
which despite no differences in BMI, waist circumference, hip circumference or metabolic 
syndrome, was greater in the SLE participants when compared to the controls.  Increased adipose 
volumes of smaller visceral adipose depots may be the precursors to chronic inflammatory state 
leading to atherosclerosis, obesity and exacerbating the inflammatory response of a disease like 
SLE. 
Women with SLE have a higher risk of CVD related events [68] and have a higher risk of 
subclinical CVD as measured through CAC [77], AC [104], pulse wave velocity [79, 116] when 
compared to healthy controls.  Given the systemic nature of CVD, descending thoracic aortic 
calcification has been found to be a strong predictor of CAC independent of CVD risk factors 
and is thus another important subclinical CVD measure of vascular calcification.[117]  Although 
the volume of aortic tPVAT is approximately two orders of magnitude less than total visceral 
adipose measures [28], there is a significant cardio-metabolic influence and association between 
this visceral adipose and AC and CAC.  In a recent study of the Framingham Heart Study 
Offspring cohort including both men and women, the descending thoracic aorta PVAT volume 
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was significantly associated with thoracic AC (1.31[1.01–1.71],p=0.04), but only when adjusting 
for visceral adipose which was then attenuated when adjusting for any CVD risk factors [29]  
This same study also reported higher OR associated with aortic PVAT and CAC in a clinically 
CVD free population; however, the population was 10 years older when compared to the 
population within this study.[29]  Within this population, AC is associated with SLE and tPVAT 
independent of cardio-metabolic factors in this group of asymptomatic participants, while the 
CAC association with tPVAT is contingent on which obesity-related factor is adjusted within the 
model.  This suggests that excessive tPVAT and AC are precursors to CAC and exacerbated 
CVD progression.  By extension, this early calcification of the aorta may contribute to the 
increase in vascular stiffness [79] and the increased number of hypertensive SLE participants 
(p<0.0001), despite no difference in waist circumference, BMI, or metabolic syndrome.  
Systemic hypertension is associated with increased frequency of CV events in SLE 
patients.[118] The visceral adipose, including aortic tPVAT, of the SLE group may follow a 
more similar pattern of dysfunction generally associated with that of chronic low grade 
inflammatory state of overweight or obese individuals.  
Surprisingly, not all of the measured circulating inflammatory markers including sICAM 
and eSelectin, were significantly correlated with tPVAT within the SLE group, both of which are 
associated with atherosclerosis in the general population.[53, 119]  ESelectin has been found to 
be higher with the presence of plaque in SLE patients [120] and general visceral adiposity [121] 
while sICAM has been found in atherosclerotic lesions, is a predictor of coronary heart disease, 
[53] and positively correlated with SLE disease activity index (SLEDAI, [122]).  SICAM has 
also been found in human epicardial tissue in obese participants and those with coronary artery 
disease. [123]  A mild association of sICAM (p=0.087) to tPVAT was detected through the 
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multivariate linear regression analyses of MS, inflammatory factors, and SLE, which suggests 
that perhaps the other inflammatory markers such as CRP are more important in a clinically 
CVD free population and that inflammatory markers such as sICAM and eSelectin may require 
more progressive CVD development or more significant SLE disease activity.  Additional 
metabolic characterization of aortic PVAT is necessary to determine if this visceral adipose 
depot indeed secretes increased amounts of pro-inflammatory products or perhaps upregulates 
the expression factors necessary to sustain inflammation. 
Additional investigation into other visceral adipose depots including quantification of the 
general intra-abdominal and distinct pericardial, epicardial and aortic arch adipose depots 
relating to the tPVAT needs to be assessed in the SLE population.  Evaluating these various 
adipose reservoirs along with the subclinical CVD measures will allow us to determine the 
adipose with the most developed cardio-metabolic influence and adipocyte dysfunction and 
elucidate if there are any early cardio-protective roles of aortic PVAT in both SLE patients and 
the broader population.  
In addition, evaluation of the metabolic profile of serum adipokine levels, including 
leptin, resistin, visfatin, and adiponectin, with tPVAT is required.  In the general US population, 
elevated circulating leptin levels are associated with MI and stroke independent of CVD risk 
factors [124], while adiponectin may modulate SLE activity and levels may be increased with 
CVD progression.[120] Perhaps changes in adipokine serum levels can be seen within a finer 
nuance of increasing tPVAT volume rather than larger depot of general visceral adipose volume.  
The control group within this study also lacked the analysis of circulating complement protein 
levels.  Aortic stiffness of the SLE women is associated with SLE specific risk factors such as 
elevated complement C3.[79]  A strong positive correlation exists between C3 levels and tPVAT 
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in SLE patients along with CAC, but no effect on AC.  Quantifying the complement proteins of 
the control group will elucidate the role of elevated circulating complement proteins in 
subclinical CVD.  In the SLE population, differentiating the apparent cause of a CV event 
whether related to atherosclerosis or active lupus can be difficult.[75]  Detecting early adipose 
dysfunction through quantification of aortic tPVAT may aid in delaying or preventing later 
arterial structural changes leading to better outcomes.  Determining if tPVAT volume is 
predictive of CV events may elevate the overall status of this visceral depot from risk factor to a 
subclinical CVD measure. 
Several limitations within this study exist and included the cross-sectional study design.  
No prognostic evaluations of PVAT can be made at this time; however, subsequent data 
collection was done on this same population with CV events, which will allow us a longitudinal 
evaluation of tPVAT.  The majority of this population is Caucasian and any extrapolation of the 
findings to other ethnicities must be done with caution.  There may be other CVD risk factors not 
included in the multivariate analyses that need to be considered when evaluating adipose tissue, 
such as adipokines. 
Cardiovascular disease is the leading cause of death of women in America and in 
developing countries and emerging economies.[1]  Young women with SLE are over 50 times 
more likely to experience a myocardial infarction when compared to healthy controls.[68]  
Traditional CVD risk factors alone do not account for this exaggerated risk and it is suspected 
that there are SLE-related factors possibly linked with the inflammatory nature of the disease 
which exacerbates the pro-inflammatory conditions of atherosclerosis and CVD development.  
This existing pro-inflammatory state may also incorporate the chronic, low-grade inflammatory 
response of the adipose tissue.  From an epidemiological and public health standpoint, both the 
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SLE population and the general population will benefit from knowledge gained in characterizing 
the role of small visceral adipose depots in the progression of CVD and its contribution to the 
inflammatory state.   
 Descending thoracic aortic PVAT is a viable, metabolically active visceral adipose depot 
with optimal location for influencing the surrounding arterial structures.  Descending thoracic 
PVAT volume is greater in asymptomatic SLE population when compared to controls despite 
other anthropomorphic measures being the same.  The PVAT volume is associated with both AC 
independently and CAC through BMI. 
 
 44 
APPENDIX 
REPRODUCIBILITY ANALYSIS 
A reproducibility analysis was performed to determine the inter- and intra-reader variability in 
determining the PVAT volume using EBCT scans.  Two readers were chosen (KJS and MG) and 
two time points approximately 3 to 4 weeks apart were chosen.  Eleven participants were 
randomly selected to use in the analysis.  
Table A1:  Descriptive statistics of PVAT volume at time point 1. Std: Standard deviation, IQR: 
Interquartile Range. 
PVAT (mm3) Mean Median Std IQR 
MG Time 1 32821.73 27844.86 17445.84 
21511.98        
38828.16 
KJSTime 1 33682.28 29243.40 17276.96 
22510.20 
39599.34 
 
Table A2:  Descriptive statistics of PVAT volume at time point 2. 
PVAT (mm3) Mean Median Std IQR 
MG Time 2 33097.11 28416.12 17369.26 
21610.20        
38799.42 
KJSTime 2 33525.31 28832.76 17113.93 
21836.82        
39019.32 
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Figure A1:  Spearman correlation matrix of PVAT volume between both readers and both time 
points. 
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Figure A2:  Linear regression of PVAT volume between both readers and both time points.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure A3:  Residuals of PVAT volume between both readers and both time points. 
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Table A3:  Descriptive difference of PVAT volume between both readers and both time points. Std: 
Standard deviation, IQR: Interquartile Range.
Difference 
PVAT (mm3) 
Mean Median Std IQR 
p-value 
µ = 0 
Paired ttest 
MG Time (2-1) 275.38 246.96 509.06 -105.6 - 666.6 0.103 
KJSTime (2-1) -156.97 -199.5 488.42 -580.02 - 154.68 0.312 
MG1-KJS1 -860.55 -771.18 472.74 -1375.74 - -498.0 0.0001 
MG2-KJS2 -428.12 -416.64 426.94 -783.24 - -178.14 0.0077 
  
Table A4:  Intraclass correlation of PVAT volume between both readers and both time points, 
DEYO Method.  
ICC MG KJS MG1 vs KJS1 MG2 vs KJS2 
DEYO's 0.999 0.999 0.998 0.999 
 
Table A5:  Intraclass correlation of PVAT volume between both readers and both time points, 
SAS REML, TYPE I Method.  ICC: Intraclass Correlation. 
volPVAT 
Between 
Subject 
Variance 
Between 
Readings 
Error Variance ICC 
MG2-MG1* 302894580 26137.2 129573.1 0.999 
KJS2-KJS1+ 295570734 1476.5 119277.4 0.999 
MG1-KJS1* 301313560 360112.3 111743.1 0.998 
MG2-KJS2* 297197722 83391.5 91138.7 0.999 
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Figure A4:  Bland-Altman plots of PVAT volume between both readers and both time points. 
 
PVAT volume data was consistent between participants with a good range of values.  
Spearman correlations were high, 1.000.  Excellent intraclass correlations were calculated by 
hand (DEYO’s Method) and through SAS (REML, TYPE I Method) ranging from 99.8-99.9% of 
the variability due to participants and not to the readers or the different time points.  There was 
some systemic bias with KJS readings consistently higher than MG readings; however the 
differences seen within the Bland-Altman show that the limits of agreement were at least one 
order of magnitude less than the PVAT volumes. 
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